Elevated glycogen synthase kinase-3 activity in Fragile X mice: Key metabolic regulator with evidence for treatment potential
- 14 October 2008
- journal article
- Published by Elsevier in Neuropharmacology
- Vol. 56 (2), 463-472
- https://doi.org/10.1016/j.neuropharm.2008.09.017
Abstract
No abstract availableKeywords
This publication has 88 references indexed in Scilit:
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- Glycogen is a preferred glutamate precursor during learning in 1‐day‐old chick: Biochemical and behavioral evidenceJournal of Neuroscience Research, 2007
- Highly Potent and Specific GSK‐3β Inhibitors That Block Tau Phosphorylation and Decrease α‐Synuclein Protein Expression in a Cellular Model of Parkinson's DiseaseChemMedChem, 2006
- Deletion of FMR1 in Purkinje Cells Enhances Parallel Fiber LTD, Enlarges Spines, and Attenuates Cerebellar Eyelid Conditioning in Fragile X SyndromeNeuron, 2005
- Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEPNeuropharmacology, 2005
- Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptorsBritish Journal of Pharmacology, 2005
- Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X SyndromeNeuron, 2005
- Reduced Cortical Synaptic Plasticity and GluR1 Expression Associated with Fragile X Mental Retardation Protein DeficiencyMolecular and Cellular Neuroscience, 2002
- Drosophila Fragile X-Related Gene Regulates the MAP1B Homolog Futsch to Control Synaptic Structure and FunctionCell, 2001
- Audiogenic Seizures Susceptibility in Transgenic Mice with Fragile X SyndromeEpilepsia, 2000